Thu.Aug 15, 2024

article thumbnail

Prices Released for First 10 Drugs Selected in Medicare Negotiations

Drug Topics

New prices will go into effect on January 1, 2026, for individuals covered by Medicare Part D prescription drugs.

198
198
article thumbnail

CMS Announces Negotiated Prices for 10 Drugs Under Inflation Reduction Act

Pharmacy Times

The new prices are expected to go into effect for patients with Medicare Part D on January 1, 2026.

149
149
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

STAT+: Medicare announces drug prices for historic first round of negotiations

STAT

WASHINGTON — The day drug makers dreaded has finally arrived.  Medicare officials on Thursday unveiled the results of the program’s first 10 drug price negotiations, despite the industry’s two-decade, multimillion-dollar lobbying campaign and barrage of lawsuits to stop them.  The drugs that received negotiated prices include Bristol Myers Squibb’s blood thinner Eliquis, Boehringer Ingelheim’s diabetes drug Jardiance, Johnson & Johnson’s bl

145
145
article thumbnail

Co-Administering RSV and Influenza Vaccines Could Provide Tolerable Immune Responses

Pharmacy Times

RSV and influenza vaccines demonstrated hemagglutination inhibition titers that were noninferior to those with sequential administration.

Vaccines 145
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Clinical trials exclude disabled Americans because federal agencies failed them, new report finds

STAT

People with disabilities are largely excluded from clinical trials that could benefit them because federal agencies have failed to update rules that govern how trials are conducted or neglected to enforce existing laws that protect disabled Americans against discrimination, a new report has found. The National Council on Disability, an independent federal agency, released the report this week detailing how several federal agencies implicitly and explicitly exclude people with disabilities from c

FDA 144
article thumbnail

CMS: Negotiated drug prices would have saved Medicare $6B last year

Fierce Healthcare

The Centers for Medicare & Medicaid Services offered the first look at the potential savings generated by the first crop of Medicare drug price negotiations. | The Centers for Medicare & Medicaid Services offered the first look at the potential savings generated by the first crop of Medicare drug price negotiations.

135
135

More Trending

article thumbnail

Wolters Kluwer targets retail pharmacies with new digital solutions for medication education

Fierce Healthcare

Information services company Wolters Kluwer rolled out new digital solutions to help retail pharmacies go paperless in an online, mobile tech consumer world. | There is a need to revamp the retail pharmacy experience beyond providing patients with medication leaflets. Two new pharmacy solutions offer digital health content to provide pharmacy consumers with accessible medication and health information.

131
131
article thumbnail

Arthritis patients resort to an inconvenient Medicare workaround to avoid pricey drugs

STAT

As many as 40,000 chronically ill seniors are choosing to endure uncomfortable, time-consuming intravenous infusions because Medicare doesn’t sufficiently cover far more convenient, and less distressing, at-home treatments with the arthritis drug Humira. When rheumatoid arthritis patients enroll in Medicare, switching from private insurance plans, self-administered medications such as Humira and Xeljanz become unaffordable overnight, thanks to the program’s convoluted pricing of at

Insurance 139
article thumbnail

FDA Grants Priory Review for Durvalumab to Treat Small Cell Lung Cancer

Pharmacy Times

The supplemental biologics license application was granted based on results from the ADRIATIC phase 3 trial among individuals with limited stage small cell lung cancer.

FDA 129
article thumbnail

STAT+: The business of CRISPR’d medicine: Not great

STAT

This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up  here  to get it delivered to their inbox. I’m really excited to see “Alien: Romulus” this weekend, which I’m told harkens back to the 1979 original. Great 1970s-era sci-fi movies and TV series that are not Star Wars: Space 1999, Battlestar Galactica, Planet of the Apes, Close Encounters of the Third Kind, and Logan’s Run.

139
139
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

As mpox outbreak spreads across Africa, Siga's antiviral Tpoxx misses the bar in Congo study

Fierce Pharma

Just as a new strain of mpox spreads across Africa, results from a preliminary analysis of a study that began during the 2022 viral outbreak stands to provide more clarity on the clinical benefit o | Despite missing the trial's primary endpoint of time to lesion resolution, the study suggested that the treatment may be most beneficial for those treated early and those with severe disease.

124
124
article thumbnail

Antiviral used for mpox no better than placebo, NIH says

STAT

The National Institutes of Health said Thursday that an antiviral often used to treat mpox did not resolve patients’ symptoms faster than placebo in a randomized trial. The results are notable because the drug, tecovirimat, has rarely been studied clinically for mpox, despite its sporadic use over the years in parts of Africa and its wider use during the 2022 and 2023 outbreaks in the U.S. and Europe.

138
138
article thumbnail

Behind the Counter: Mastering Pseudoephedrine and Other Restricted OTC Medications

Pharmacy Times

Key opinion leaders analyze the efficacy, safety profile, and proper utilization of behind-the-counter medications such as pseudoephedrine products, exploring their mechanisms of action and potential adverse effects, while also providing strategies for pharmacists to identify contraindications, drug interactions, and appropriate dosing regimens for these medications.

123
123
article thumbnail

STAT+: Boston’s lab market is in rough shape

STAT

When demand for office space cratered during the Covid-19 pandemic, many developers in the Boston area doubled down on building lab space instead. Lately, it sure seems like they went overboard. With life sciences buildings hitting the market at a much faster rate than they can be filled, the region’s lab vacancy rate has skyrocketed, to the point that the share of empty space available rivals that of the pandemic-battered office market.

128
128
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

Maintaining Good Oral Hygiene Is the Gateway to General Health and Well-Being

Pharmacy Times

Some individuals are still unaware of the significance of routine oral hygiene and its link to overall health

122
122
article thumbnail

STAT+: Lykos Therapeutics cuts 75% of staff after FDA rejects MDMA-assisted therapy

STAT

Lykos Therapeutics, whose MDMA-assisted psychotherapy for post-traumatic stress disorder was rejected late last week by U.S. regulators, announced Thursday that it would cut 75% of its staff, and that the company’s founder would step down from its board. “We take to heart the FDA’s decision and the additional work we will need to do to bring this pioneering therapy to market,” Jeff George, chairman of the board, said in a statement.

FDA 126
article thumbnail

US court rules for AstraZeneca, erasing Pfizer's $107.5M jury award in patent infringement case

Fierce Pharma

Less than three months after a Delaware federal jury ordered AstraZeneca to pay $107.5 million to Pfizer in a patent infringement case, a Delaware judge has nullified the award and invalidated the | Less than three months after a Delaware federal jury ordered AstraZeneca to pay $107.5 million to Pfizer in a patent infringement case, a Delaware judge has nullified the award and invalidated the patents behind the original lawsuit.

121
121
article thumbnail

Opinion: HHS says it is working against climate change. But it’s really climate washing

STAT

The U.S. Department of Health and Human Services has stated it will do all that it can to mitigate the health care industry’s greenhouse gas emissions. The evidence suggests it is climate washing. Climate washing is defined as a government or business providing inadequate, inaccurate, misleading, or false public information about its climate policy ambitions or implementation efforts to reduce greenhouse gas emissions, especially when the claims are made without independent third-party as

article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

AI as an inventor: Defining ownership in the pharma sector

pharmaphorum

AI's role in inventing new drugs raises questions about ownership rights in the pharmaceutical sector. Explore the complexities of defining ownership in drug discovery with AI technology.

117
117
article thumbnail

STAT+: UnitedHealthcare’s latest contract dispute, this time with Trinity Health, leaves thousands out-of-network 

STAT

A widespread, monthslong contract dispute between UnitedHealthcare and Trinity Health has created a confusing patchwork of disrupted access across multiple states.  UnitedHealthcare is the country’s largest health insurer, so its contract disagreements with large health systems affect members across the country from one another, threatening access to dozens of hospitals and their affiliated physicians.

Hospitals 116
article thumbnail

AstraZeneca said to be wavering on £450m UK vaccine plant

pharmaphorum

AstraZeneca's plan to invest £450m in a vaccines plant in the UK has been thrown into doubt by a bid to slash state aid, reports FT

Vaccines 115
article thumbnail

As Fall Allergy Season Approaches, Encourage Patients to Begin Medicating Today

Drug Topics

Ragweed season begins in late August and can run through early November.

112
112
article thumbnail

Allstate sells off employer voluntary benefits unit in $2B deal

Fierce Healthcare

Insurance giant Allstate will sell off its employer voluntary benefits arm to StanCorp Financial Group, also known as the Standard, in a deal valued at $2 billion. | Insurance giant Allstate will sell off its employer voluntary benefits arm to StanCorp Financial Group, also known as the Standard, in a deal valued at $2 billion.

Insurance 111
article thumbnail

Social, Economic Barriers Impact Access to Opioid Use Disorder Medications

Drug Topics

Community pharmacies in counties with high racialized economic segregation had higher odds of restricting buprenorphine.

article thumbnail

Incyte builds GvHD presence with Niktimvo approval

pharmaphorum

FDA clears Incyte's potential blockbuster Niktimvo as a treatment for chronic GvHD, making it a companion to the company's Jakafi for the disorder.

FDA 111
article thumbnail

Despite Success of Vaccines for Children Program, Disparities Persist

Drug Topics

A CDC report called for “increased efforts” to ensure parents can obtain all recommended vaccines for their eligible children and realize the full potential of the VFC program.

Vaccines 112
article thumbnail

AI chatbots struggle to interpret patient descriptions

pharmaphorum

Large language models (LLMs) find it hard to identify genetic conditions based on patient-written descriptions, say NIH researchers.

111
111
article thumbnail

New Solutions from UpToDate Offer Accessible, Sustainable Patient Education

Drug Topics

As the role of pharmacists continues to change, new digital tools can help improve medication adherence and patient outcomes.

112
112
article thumbnail

We have mpox vaccines now. But how will they be distributed?

STAT

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. Good morning. Big news this morning, so let’s get straight into it.

Vaccines 110
article thumbnail

ELM-2 Trial Indicates Odronextamab Effective, Safe in Patients With Follicular Lymphoma

Pharmacy Times

Building off the positive results of ELM-1, the ELM-2 trial found intravenously administered odronextamab was safe and effective in patients with relapsed or refractory follicular lymphoma.

107
107
article thumbnail

New Medicare drug prices, antimicrobial-resistant meningitis, unlucky American women

STAT

Want to stay on top of health news?  Sign up  to get our Morning Rounds newsletter in your inbox. Almost exactly two years ago, the Inflation Reduction Act was signed into law, allowing Medicare to negotiate drug prices for the first time. Today, the agency announced how much it lowered the costs for 10 drugs in the first year of negotiation.

107
107
article thumbnail

How clinical trials can use AI responsibly and effectively

Pharmaceutical Technology

Strong measures must be in place to safeguard confidential patient data when deploying AI to optimise clinical trial translations.

107
107
article thumbnail

PBC drug choices rise in US with OK for Gilead's seladelpar

pharmaphorum

FDA approves Gilead's Livdelzi for primary biliary cholangitis, setting up a contest with Ipsen's recent launch Iqirvo in the second-line setting

FDA 105